Lymphocytic hypophysitis (autoimmune hypophysitis, incl. ICI-induced)
Autoimmune-mediated inflammation of the pituitary gland and/or pituitary stalk causing pituitary dysfunction. Subtypes by anatomic involvement: LYMPHOCYTIC ADENOHYPOPHYSITIS (anterior pituitary only — classic primary form; female predominance ~6:1; presents in late pregnancy or postpartum); LYMPHOCYTIC INFUNDIBULONEUROHYPOPHYSITIS (stalk + posterior pituitary — presents primarily with AVP-D); LYMPHOCYTIC PANHYPOPHYSITIS (both compartments). Pathology: dense lymphocytic + plasma cell infiltrate of the pituitary; eventual fibrosis and atrophy. Etiologies: PRIMARY AUTOIMMUNE (classic non-ICI form; pregnancy/postpartum predilection; associated with Hashimoto's + T1DM + Addison's + autoimmune polyglandular syndromes); **IMMUNE CHECKPOINT INHIBITOR (ICI)-INDUCED = MODERN EPIDEMIC** — ipilimumab (anti-CTLA-4) most strongly associated; nivolumab + pembrolizumab (anti-PD-1) also cause it; combination ipilimumab + nivolumab highest incidence ~10-17%; presents weeks to months after ICI initiation; IgG4-RELATED HYPOPHYSITIS (overlapping with IgG4-RD spectrum); GRANULOMATOUS HYPOPHYSITIS (sarcoidosis, TB, syphilis, Langerhans cell histiocytosis); XANTHOMATOUS HYPOPHYSITIS (rare). Clinical features: headache (mass-effect from inflammatory swelling — sella enlargement); visual disturbances (chiasmal compression — visual field defects, decreased acuity); adenohypophyseal dysfunction (ACTH deficiency = adrenal crisis risk; central hypothyroidism; central hypogonadism; GH deficiency; hyperprolactinemia from stalk effect or hypoprolactinemia from lactotroph destruction); infundibuloneurohypophysitis = AVP-D. Diagnostics: pituitary MRI with gadolinium = thickened pituitary stalk + symmetric pituitary enlargement + diffuse gadolinium enhancement + loss of posterior bright spot (if posterior involved); biochemical workup (full anterior pituitary axis screen + cortisol axis priority; serum sodium + osmolality for AVP-D); anti-pituitary antibodies (limited clinical utility); biopsy (reserved for atypical cases). Differential: pituitary adenoma, craniopharyngioma, metastasis, sarcoidosis, IgG4-RD. For ICI-induced: ICI exposure history with appropriate timing makes diagnosis clinical. Management: HORMONE REPLACEMENT BY DEFICIENT AXIS — hydrocortisone (CORTISOL REPLACEMENT IS LOAD-BEARING + STRESS-DOSE PROTOCOLS); levothyroxine; sex hormones; desmopressin if AVP-D involved; somatropin if confirmed adult GHD. Corticosteroids for active inflammation in primary autoimmune disease (historically high-dose prednisone 0.5-1 mg/kg tapered over months; mixed efficacy data); azathioprine + methotrexate + rituximab as steroid-sparing options. **ICI-induced consensus shift (last 5 years)**: HIGH-DOSE CORTICOSTEROIDS NO LONGER ROUTINELY RECOMMENDED for ICI hypophysitis (does NOT improve recovery of pituitary function); replacement-only approach for most cases; HOLD ICI for moderate-severe; restart ICI typically possible after adrenal axis stable on replacement. Endocrine Society + ESE 2018 + EAU Pituitary Working Group + Society for Immunotherapy of Cancer (SITC) toxicity guidelines + Pituitary Network Association. **Editorial**: GH-axis peptides (CJC + tesa + ipa) Tier 2 — pituitary IS the failed organ from inflammation/destruction; same archetypal wrong-direction as hypopituitarism + tesa label contraindicates pituitary tumor history (hypophysitis presents AS sellar mass on imaging). TA-1 Rule 6 wrong-direction (T-cell activation in T-cell-mediated autoimmune destruction; compounded for ICI-induced — disease IS downstream of T-cell checkpoint release). LL-37 autoimmune-contraindication thread (documented autoantigen behavior). BPC-157 pro-angiogenic in actively inflamed pituitary. NMN no autoimmune-pituitary engagement. Sixtieth deliberate non-elevation.
What changes during this transition
Lymphocytic hypophysitis is autoimmune-mediated inflammation of the pituitary gland and/or pituitary stalk, with anatomic subtypes by compartment involvement: lymphocytic adenohypophysitis (anterior pituitary only — the classic primary form, with marked female predominance and a strong predilection for late pregnancy and the postpartum period), lymphocytic infundibuloneurohypophysitis (stalk plus posterior pituitary, presenting primarily with arginine-vasopressin deficiency), and lymphocytic panhypophysitis (both compartments). Etiologically the disease has shifted: primary autoimmune hypophysitis remains the classic non-oncologic presentation (often clustered with other autoimmune conditions — Hashimoto's, type 1 diabetes, Addison's, autoimmune polyglandular syndromes), but immune-checkpoint-inhibitor-induced hypophysitis is now the modern epidemic, with ipilimumab (anti-CTLA-4) carrying the strongest association, the anti-PD-1 agents nivolumab and pembrolizumab also implicated, and combination ipilimumab plus nivolumab reaching the highest incidence at roughly 10-17% of treated patients. IgG4-related hypophysitis (overlapping with the broader IgG4-RD spectrum), granulomatous hypophysitis (sarcoidosis, TB, syphilis, Langerhans cell histiocytosis), and xanthomatous hypophysitis round out the rarer etiologies. Clinical presentation reflects both the inflammatory mass and the resulting hormone deficits: headache and visual disturbances from sellar enlargement and chiasmal compression; adenohypophyseal dysfunction (ACTH deficiency carrying the load-bearing adrenal crisis risk, plus central hypothyroidism, central hypogonadism, GH deficiency, and either hyperprolactinemia from stalk effect or hypoprolactinemia from lactotroph destruction); and AVP-D (polyuria, polydipsia, hypernatremia risk) when the posterior pituitary or stalk are involved. Diagnostic imaging shows symmetric pituitary enlargement, thickened pituitary stalk, diffuse gadolinium enhancement, and loss of the posterior bright spot in posterior involvement — distinguishing this from pituitary adenoma, craniopharyngioma, metastasis, and other sellar lesions. Anti-pituitary antibodies have limited clinical utility; biopsy is reserved for atypical cases where mass lesion cannot otherwise be excluded. Management centers on hormone replacement by deficient axis — hydrocortisone with stress-dose protocols is load-bearing whenever ACTH deficiency is present, joined by levothyroxine, sex hormones, desmopressin for AVP-D, and somatropin if adult GHD is confirmed. Corticosteroids for active inflammation are used selectively in primary autoimmune disease (historically high-dose prednisone tapered over months, with mixed efficacy data), with azathioprine, methotrexate, or rituximab as steroid-sparing options in refractory cases. ICI-induced disease has undergone a consensus shift over the last five years: high-dose corticosteroids are no longer routinely recommended because they do not improve recovery of pituitary function, with a replacement-only approach now standard for most cases, ICI typically held during acute presentation and often restarted once the adrenal axis is stable on replacement. Editorially, this is substrate that exists for /ask honesty: patients facing this diagnosis are often simultaneously navigating cancer treatment or new-baby logistics, and the peptide-community questions that arise (BPC-157 for general healing, GH-axis peptides for hormone-stimulation framing, immune-modulator peptides like thymosin alpha-1 or LL-37) deserve direct, honest mechanistic answers — most of which point back to the same load-bearing reality: missed or under-dosed hydrocortisone is the actual acute safety risk, and the established replacement and selective immunosuppression algorithms run by endocrinology (with oncology in the ICI-induced setting) are where care lives. Reference frameworks: Endocrine Society guidelines on hypopituitarism, ESE 2018 consensus on hypophysitis, EAU Pituitary Working Group recommendations, Society for Immunotherapy of Cancer (SITC) toxicity guidelines for ICI-related endocrinopathies, and Pituitary Network Association patient resources. Sixtieth deliberate non-elevation.
Important caveat
Lymphocytic hypophysitis is managed by endocrinology, with oncology co-management for the ICI-induced subset. **ADRENAL CRISIS IS THE LOAD-BEARING ACUTE SAFETY RISK** — ACTH deficiency requires hydrocortisone replacement (15-25 mg/day divided) PLUS stress-dose protocols for illness / surgery / trauma PLUS an EMERGENCY INJECTION KIT PLUS medical alert. Missed or under-dosed hydrocortisone is the actual failure mode. **REPLACEMENT-FIRST APPROACH FOR ICI-INDUCED**: the last 5 years have seen a consensus shift away from high-dose corticosteroids for ICI-induced hypophysitis — they do NOT improve recovery of pituitary function. Replacement-only approach is now standard; hold ICI for moderate-severe; restart typically possible once adrenal axis stable on replacement; cancer benefit often outweighs hypopituitarism. **PRIMARY AUTOIMMUNE PREGNANCY/POSTPARTUM PRESENTATION**: female predominance ~6:1; late pregnancy and postpartum are the peak windows; symptoms (headache + fatigue + galactorrhea changes + hypoglycemia + amenorrhea) overlap with postpartum recovery and routinely get diagnosed late. **IMAGING IS DIAGNOSTIC**: pituitary MRI shows symmetric pituitary enlargement + thickened stalk + diffuse gadolinium enhancement + loss of posterior bright spot if posterior involved. Differential includes pituitary adenoma, craniopharyngioma, metastasis, sarcoidosis, IgG4-RD — and patients post-hypophysitis often carry 'pituitary lesion' notes in their imaging history that affect downstream prescribing decisions. **GH-AXIS PEPTIDES (CJC-1295, tesamorelin, ipamorelin) ARE TIER 2 MECHANISTICALLY WRONG-DIRECTION**: pituitary IS the failed organ from autoimmune inflammation/destruction; same archetypal error as hypopituitarism (upstream stimulation cannot recruit destroyed somatotrophs). If GHD is confirmed, somatropin is the established replacement. Tesamorelin's FDA label additionally contraindicates pituitary tumor history — and lymphocytic hypophysitis can leave 'pituitary lesion' or 'sellar enlargement' in your imaging history. **THYMOSIN ALPHA-1 IS RULE 6 WRONG-DIRECTION**: TA-1's established direction of effect is T-cell maturation/activation (CD4/CD8 differentiation, IL-2 production, Th1-skewed responses); lymphocytic hypophysitis is T-cell-mediated autoimmune destruction. Pushing T-cell activation in T-cell-mediated autoimmune disease is the wrong direction. Compounded for ICI-induced disease — ICIs work by releasing T-cell checkpoints, and the resulting hypophysitis is already downstream of that; adding another T-cell-activating agent into that picture is the kind of decision that needs joint oncology-endocrinology weight-in. Registered TA-1 indications (HBV, oncology adjuvant) don't transfer. **LL-37 AUTOIMMUNE-CONTRAINDICATION THREAD**: documented autoantigen behavior in psoriasis (T-cell responses to LL-37/DNA complexes), elevated expression in SLE + RA; introducing an exogenous peptide with autoantigen behavior into an active autoimmune process against pituitary tissue is the wrong direction. **BPC-157**: no hypophysitis characterization; pro-angiogenic VEGF / eNOS in an actively inflamed pituitary is wrong-direction; not part of any algorithm. **NMN**: general-aging; doesn't engage autoimmune-pituitary biology; under-replaced cortisol mimics 'general fatigue' and is the higher-yield axis to address first. **DESMOPRESSIN** if AVP-D component (cross-reference AVP-D entry — desmopressin is itself a peptide therapy and the standard of care for AVP-D). **POST-HYPOPHYSITIS GHD STIMULATION TESTING**: dynamic GH stim (ITT, GHRH-arginine, glucagon) is standard — IGF-1 alone undershoots; somatropin titrated to mid-range age-adjusted IGF-1; adrenal axis assessed FIRST (GH replacement unmasks secondary adrenal insufficiency). Endocrine Society + ESE 2018 + EAU Pituitary Working Group + SITC toxicity guidelines + Pituitary Network Association patient resources. WADA athletes: peptide GH secretagogues prohibited at all times; somatropin replacement requires TUE; hydrocortisone replacement requires TUE. Pregnancy: primary autoimmune presents in pregnancy/postpartum; co-manage endocrinology + maternal-fetal medicine; stress-dose protocols continue through labor + delivery. Cancer treatment context for ICI-induced: oncology owns the cancer-benefit-vs-hypopituitarism conversation; do not introduce peptide-clinic adjuncts in isolation.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.